VSV-hIFNbeta-NIS with or without Ruxolitinib Phosphate in Treating Patients with Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, or T-cell Lymphoma
- Relapsed or refractory: * Multiple myeloma (MM) previously treated with an immunomodulatory drug (IMID), a proteosome inhibitor and an alkylating agent; OR * Acute myeloid leukemia (AML), excluding acute promyelocytic leukemia (PML-RARA rearranged- AML-M3); either primary refractory or relapsed/refractory disease after at least two front line chemotherapy regimens (note: induction and consolidation chemotherapy is considered one line of therapy); diagnosis based on 2008 World Health Organization (WHO) criteria; OR * Relapsed T-cell lymphoma (TCL) or the following types: peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS); angioimmunoblastic T-cell lymphoma (AITL), anaplastic large cell (ALCL), and cutaneous TCL (CTCL) of mycosis fungoides (MF); patients should have failed standard therapy and in the case of PTCL-NOS, AITL, and ALCL either have failed or be ineligible for high-dose therapy with autologous stem cell transplant
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2 times upper limit of normal (ULN) (obtained =< 14 days prior to registration)
- Creatinine =< 2.0 mg/dL (obtained =< 14 days prior to registration)
- Direct bilirubin =< 1.5 x ULN (obtained =< 14 days prior to registration)
- International normalized ratio (INR)/prothrombin time (PT) and activated partial thromboplastin time (aPTT) =< 1.5 x ULN (obtained =< 14 days prior to registration)
- If baseline liver disease, Child Pugh score not exceeding class A (obtained =< 14 days prior to registration)
- Negative pregnancy test for persons of child-bearing potential (obtained =< 14 days prior to registration)
- FOR MULTIPLE MYELOMA ONLY: Measurable disease of multiple myeloma as defined by at least ONE of the following: * Serum monoclonal protein >= 1.0 g/dL by protein electrophoresis * >= 200 mg of monoclonal protein in the urine on 24-hour electrophoresis * Serum immunoglobulin free light chain >= 10 mg/dL AND abnormal serum immunoglobulin kappa to lambda free light chain ratio
- FOR MULTIPLE MYELOMA ONLY: Absolute neutrophil count (ANC) >= 1000/uL (obtained =< 14 days prior to registration)
- FOR MULTIPLE MYELOMA ONLY: Platelet (PLT) >= 100,000/uL (obtained =< 14 days prior to registration)
- FOR MULTIPLE MYELOMA ONLY: Hemoglobin >= 8.5 g/dl (obtained =< 14 days prior to registration)
- FOR AML ONLY: No ANC restriction (obtained =< 14 days prior to registration)
- FOR AML ONLY: PLT >= 10,000/uL (transfusion to get platelets >= 10,000 is allowed) (obtained =< 14 days prior to registration)
- FOR AML ONLY: Hemoglobin >= 7.5 g/dl (obtained =< 14 days prior to registration)
- FOR AML ONLY: Absence of uncompensated disseminated intravascular coagulation (DIC- as diagnosed by standard International Society on Thrombosis and Hemostasis [ISTH] criteria)
- FOR TCL ONLY: ANC >= 1,000/uL (obtained =< 14 days prior to registration)
- FOR TCL ONLY: PLT >= 100,000/uL (obtained =< 14 days prior to registration)
- FOR TCL ONLY: Hemoglobin >= 8.5 g/dl (obtained =< 14 days prior to registration)
- FOR TCL ONLY: Measurable disease by CT or magnetic resonance imaging (MRI): must have at least one lesion that has a single diameter of > 2 cm or tumor cells in the blood > 5 x10^9/L; NOTE: skin lesions can be used if the area is > 2 cm in at least one diameter and photographed with a ruler and the images are available in the medical record
- Absence of active central nervous system (CNS) involvement; NOTE: pre-enrollment lumbar puncture not mandatory
- Ability to provide written informed consent
- Willingness to return to Mayo Clinic in Rochester, Minnesota for follow-up
- Life expectancy >= 12 weeks
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, or 2
- Willing to provide mandatory biological specimens for research purposes
- Availability of and patient acceptance of curative therapy
- Uncontrolled infection
- Active tuberculosis or hepatitis, or history of hepatitis B or C, or chronic hepatitis
- Any of the following prior therapies: * Chemotherapy (IMIDs, alkylating agents, proteosome inhibitors) =< 2 weeks prior to registration * Immunotherapy (monoclonal antibodies) =< 4 weeks prior to registration * Experimental agent in case of AML or TCL within 4 half-lives of the last dose of the agent
- New York Heart Association classification III or IV, known symptomatic coronary artery disease, or symptoms of coronary artery disease on systems review, or known cardiac arrhythmias (atrial fibrillation or supraventricular tachycardia [SVT])
- Active CNS disorder or seizure disorder or known CNS disease or neurologic symptomatology; in case of AML active CNS involvement as detected by lumbar puncture or neuro-imaging (only to be done if clinically indicated)
- Human immunodeficiency virus (HIV) positive test result or other immunodeficiency or immunosuppression
- Other concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy considered investigational (used for a non-Food and Drug Administration [FDA] approved indication and in the context of a research investigation); * NOTE: in AML, the concurrent use of hydroxyurea to help control proliferative counts is allowed throughout the treatment protocol; * NOTE: in TCL, patients may use topical emollients or corticosteroids, acetic acid soaks, etc. to control pruritis and prevent infection; no topical chemotherapy is allowed (no topical nitrogen mustard)
- Any of the following: * Pregnant women or women of reproductive ability who are unwilling to use effective contraception * Nursing women * Men who are unwilling to use a condom (even if they have undergone a prior vasectomy) while having intercourse with any woman, while taking the drug and for 4 weeks after stopping treatment
- Prior allogeneic bone marrow transplant
- AML ONLY: Current disseminated intravascular coagulopathy (DIC)
- ADDITION EXCLUSION CRITERIA FOR GROUP A (LOW TUMOR BURDEN) ONLY
- AML ONLY: Acute promyelocytic leukemia (PML-RARA rearranged- AML-M3)
- AML ONLY: AML with > 30% circulating blasts and > 50% bone marrow blasts
- MULTIPLE MYELOMA ONLY: Multiple : >= 15% plasmas cells or plasmacytoma > 5 cm in largest diameter
- TCL ONLY: Any mass >= 5 cm
I. To determine the maximum tolerated dose (MTD) of VSV-hIFNbeta-NIS (alone and in combination with ruxolitinib phosphate [ruxolitinib]) in patients with relapsed/refractory multiple myeloma, acute myeloid leukemia, or T-cell lymphoma.
I. To determine the safety profile of VSV-hIFNbeta-NIS (alone and in combination with ruxolitinib).
II. To estimate clinical response rate of VSV-hIFNbeta-NIS (alone and in combination with ruxolitinib) in patients with relapsed/refractory multiple myeloma, acute myeloid leukemia, or T-cell lymphoma overall and by disease type.
III. To estimate progression-free and overall survival of VSV-hIFNbeta-NIS (alone and in combination with ruxolitinib) in patients with relapsed/refractory multiple myeloma, acute myeloid leukemia, or T-cell lymphoma overall and by disease type.
I. To determine the time course of viral gene expression and virus elimination, and the biodistribution of virally infected cells at various times points after infection with VSV-hIFNbeta-NIS using planar and single photon emission computed tomography (SPECT)/computed tomography (CT) imaging.
II. To assess virus replication, viremia, viral shedding in urine and respiratory secretions, and virus persistence after systemic administration of VSV-hIFNbeta-NIS.
III. To characterize the pharmacodynamics (PD) of VSV-IFNbeta-NIS by way of measuring serum interferon-beta and also vesicular stomatitis virus (VSV)-real time (RT)-polymerase chain reaction (PCR) of VSV-IFNbeta-NIS.
IV. Assess CD8+ T cell (both general and VSV-IFNbeta-NIS specific) and natural killer (NK) cell responses.
V. Gene expression analysis pre- and post-virotherapy.
VI. Assess presence of VSV in tumor and normal tissues subsequent to administration of intravenous (IV) VSV-IFNbeta-NIS.
OUTLINE: This is a dose escalation study of VSV-IFNbeta-NIS. Patients are assigned to 1 of 2 groups.
GROUP A: Patients receive VSV-IFNbeta-NIS intravenously (IV) over 30 minutes on day 1. Patients undergo SPECT/CT scans at baseline, and at days 3 and 8 after VSV-IFNbeta-NIS infusion.
GROUP B: Patients receive VSV-IFNbeta-NIS IV over 30 minutes on day 1 and ruxolitinib phosphate orally (PO) twice daily (BID) on days -1 to 9. Patients undergo SPECT/CT scans at baseline, and at days 3 and 8 after VSV-IFNbeta-NIS infusion.
After completion of study treatment, patients are followed up for 28 days, and then every 3 months for up to 1 year or until progressive disease, then every 6 months for 1 year.
Trial Phase Phase I
Trial Type Treatment
Martha Q. Lacy
- Primary ID MC1684
- Secondary IDs NCI-2017-00049
- Clinicaltrials.gov ID NCT03017820